🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. DoriDuo, Mebocaína Anti-Inflam, 1.2 mg + 3 mg, comprimidos para chupar, Placebo to Test and Comparator

    Medice Arzneimittel Pütter GmbH & Co. KG

    acute pharyngitis

    phase 3 small molecule active

    1 trial

  2. Doripenem

    Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    Ventilator-Associated Pneumonia

    phase 3 small molecule terminated

    1 trial

  3. Dostarlimab

    GlaxoSmithKline

    Neoplasms, Head and Neck

    phase 3 small molecule active

    1 trial

  4. Double encapsulated oral transplant of fecal microbiota, Enema transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota, Placebo coloscopic transplant of Fecal microbiota

    Pari Pharma GmbH

    Primary Sclerosing Cholangitis

    phase 3 small molecule active

    1 trial

  5. Double encapsulated oral transplant of fecal microbiota, Placebo double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Severe Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  6. Double-blind 200 mg imsidolimab

    Vanda Pharmaceuticals Netherlands B.V.

    Generalized Pustular Psoriasis

    phase 3 small molecule terminated

    1 trial

  7. Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Cream (Test) vs. Lotricomb® Cream (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin

    Alphapharm Pty Ltd

    moderate to severely inflamed candidiasis of the skin

    phase 3 other active

    1 trial

  8. Doxorubicine + docetaxel sequential

    Sanofi Pasteur

    Breast Neoplasms

    phase 3 small molecule completed

    1 trial

  9. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  10. Doxycycline (200mg/day) or Placebo

    United Therapeutics Europe Ltd

    Persian Gulf Syndrome

    phase 3 small molecule completed

    1 trial

  11. Drisapersen

    BioMarin Pharmaceutical Australia Pty Ltd

    Muscular Dystrophies

    phase 3 small molecule terminated

    2 trials

  12. Duloxetine

    Pacira Ireland Limited

    Knee Osteoarthritis

    phase 3 small molecule completed

    1 trial

  13. Dupilumab

    Regeneron UK Limited

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  14. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  15. Dupilumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  16. Dupixent 200 mg solution for injection in pre-filled syringe, Dupixent 300 mg solution for injection in pre-filled pen, Dupixent 300 mg solution for injection in pre-filled syringe, Dupixent 200 mg solution for injection in pre-filled pen

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 3 small molecule active

    1 trial

  17. Durvalumab

    AstraZeneca

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  18. Durvalumab

    AstraZeneca

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  19. Durvalumab

    AstraZeneca

    Hepatocellular Carcinoma

    phase 3 small molecule active

    2 trials

  20. Duvakitug, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  21. Duvakitug, matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Immune system diseases

    phase 3 small molecule active

    1 trial

  22. Dydrogesterone 30 mg

    Abbott Australasia Pty Ltd

    Female Infertility

    phase 3 small molecule completed

    1 trial

  23. Dysport Placebo Solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection

    Ipsen

    Chronic migraine

    phase 3 small molecule active

    1 trial

  24. Dysport Placebo Solution for injection, Botulinum Toxin Type A 300 units Powder for solution for injection, Botulinum Toxin Type A 500 units Powder for solution for injection

    Ipsen

    Episodic Migraine

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources